Long-acting inhaled β 2 agonists (LABAs) in children and the new "black box" warning

Pediatric Asthma, Allergy and Immunology

Volumn 19, Issue 2, 2006, Pages 126-131

  Kelly, H William ^a,b,c  

^a Department of Pediatrics   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE PROPIONATE; FORMOTEROL FUMARATE; LONG ACTING DRUG; SALBUTAMOL; SALMETEROL;

AGE; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CHILD HOSPITALIZATION; CHILDHOOD DISEASE; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG LABELING; DRY POWDER; FOOD AND DRUG ADMINISTRATION; HUMAN; LUNG FUNCTION; METERED DOSE INHALER; OFF LABEL DRUG USE; PATIENT COMPLIANCE; POWDER INHALER; PRIORITY JOURNAL; REVIEW;

EID: 33745728781     PISSN: 08831874     EISSN: None     Source Type: Journal    
DOI: 10.1089/pai.2006.19.126     Document Type: Review

References (38)

1. National Institutes of Health: National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the diagnosis and management of asthma update on selected topics 2002. J Allergy Clin Immunol 2002; 110:8142-8219.
2. National Institutes of Health: National Heart, Lung, and Blood Institute. Global Initiative for Asthma. Global strategy for asthma management and prevention revised (2002). NHLB1/WHO Workshop Report. Bethesda, MD: NIH publication No. 02-3659, 2002.
3. Tattersfield AE, Postma DS, Barnes PJ, Svensson K, Bauer CA, O'Byrne PM, Lofdahl CG, Pauwels RA, Ullman A. Exacerbations of asthma-A descriptive study of 425 severe exacerbations. Am J Respir Crit Care Med 1999; 160:594-599.
4. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, Tattersfield A. Low dose inhaled budesonide and formoterol in mild persistent asthma: The OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164:1392-1397.
5. Pauwels RA, Löfdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337:1405-1411.
6. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJH, Pauwels RA, Pedersen SE. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study. Am J Respir Crit Care Med 2004; 170:836-844.
7. US Food and Drug Administration. Medical officer review. Provided for meeting of Pulmonary-Allergy Drugs Advisory Committee, July 13, 2005. Available at: http://www.fda/gov/ohrms/dockets/ac/05/briefing/. Last accessed March 11, 2006.
8. Leung DY, Nelson HS, Szefler SJ (eds). J Allergy Clin Immunol 2006; 117:3-44.
9. Physicians' Desk Reference. PDR® Electronic Library, Release 2005. 1.2A, Montvale, NJ: Thomson PDR, 2004.
10. Murphy S, Roberts R. "Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk. J Allergy Clin Immunol 2006; 117:34-39.
11. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The salmeterol multicenter asthma research trial: A comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129:15-26.
12. Mann M, Chowdhury B, Sullivan E, Nicklas R, Anthracite R, Meyer RJ. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 2003; 124:70-74.
13. Bensch G, Berger WE, Blokhin BM, Socolovsky AL, Thomson MH, Till MD, Castellsague J, Della Cioppa G. One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma. Ann Allergy Asthma Immunol 2002; 89:180-190.
14. Kelly HW, Harkins MS, Boushey H. The role of inhaled long-acting beta-2 agonists in the management of asthma. J Natl Med Assoc 2006; 98:8-16.
15. Nelson HS. Is there a problem with inhaled long-acting β-adrenergic agonists. J Allergy Clin Immunol 2006; 117:3-16.
16. Matz J, Emmett A, Rickard K, Kalberg C. Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: An analysis of asthma exacerbations. J Allergy Clin Immunol 2001; 107:783-789.
17. Walters JA, Wood-Baker R, Walters EH. Long-acting beta2-agonists in asthma: An overview of Cochrane systematic reviews. Respir Med 2005; 99(4):384-395.
18. 2 agonist monotherapy vs. continued therapy with inhaled corticosteroids in patients with persistent asthma: A randomized controlled trial. JAMA 2001; 285:2583-2593.
19. Lemanske RF Jr, Sorkness CA, Mauger EA, Lazarus SC, Boushey HA, Fahy JV, Drazen JM, Chinchilli VM, Craig T, Fish JE, Ford JG, Israel E, Kraft M, Martin RJ, Nachman SA, Peters SP, Spahn JD, Szefler SJ. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: A randomized controlled trial. JAMA 2001; 285:2594-2603.
20. Korosec M, Novak RD, Myers E, Skowronski M, McFadden ER Jr. Salmeterol does not compromise the bronchodilator response to albuterol during acute episodes of asthma. Am J Med 1999; 107:209-213.
21. 2 adrenoceptor polymorphism. Thorax 2000; 55:762-767.
22. 2 agonists: Issues in the management of asthma. Ann Pharmacother 2005; 39:931-938.
23. Wolfe J, LaForce C, Friedman B, Sokol W, Till D, Cioppa GD, van As A. Formoterol, 24 μg bid, and serious asthma exacerbations: Similar rates compared with formoterol, 12 μg bid, with and without extra doses taken on demand, and placebo. Chest 2006; 129:27-38.
24. 2 agonists on exacerbation rates of asthma in children. Pediatr Pulmonol 2003; 36:391-398.
25. Tal A, Simon G, Vermeulen JH, Petru V, Cobos N, Everard ML, de Boeck K. Budesonide/formoterol in a single inhaler vs. inhaled corticosteroids alone in the treatment of asthma. Pediatr Pulmonol 2002; 34:342-350.
26. Simons FER. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. N Engl J Med 1997; 337:1659-1665.
27. Russell G, Williams DA, Weller P, Price JF. Salmeterol xinafoate in children on high dose inhaled steroids. Ann Allergy Asthma Immunol 1995; 75:423-428.
28. Malone R, LaForce C, Nimmagadda S, Schoaf L, House K, Ellsworth A, Dorinsky P. The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma. Ann Allergy Asthma Immunol 2005; 95:66-71.
29. Zimmerman B, D'Urzo A, Berube D. Efficacy and safety of formoterol Turbuhaler when added to inhaled corticosteroid treatment in children with asthma. Pediatr Pulmonol 2004; 37:122-127.
30. Verberne AA, Frost C, Roorda RJ, van der Laag H, Kerrebijn KF. One-year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group. Am J Respir Crit Care Med 1997; 156:688-695.
31. Greening AP, Wind P, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344:219-224.
32. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153:1481-1488.
33. Verberne AAPH, Frost C, Duiverman EJ, Grol MH, Kerrebijn KF. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. Am J Respir Crit Care Med 1998; 158:213-219.
34. Meijer GG, Postma DS, Mulder PGH, van Aalderen WM. Long-term circadian effects of salmeterol in asthmatic children treated with inhaled corticosteroids. Am J Respir Crit Care Med 1995; 152:1887-1892.
35. Van den Berg NJ, Ossip MS, Hederos CA, Anttila H, Ribeiro BL, Davies PI. Salmeterol/fluticasone propionate (50/100 μg) in combination in a Diskus™ inhaler (Seretide™) is effective and safe in children with asthma. Pediatr Pulmonol 2000; 30:97-105.
36. Szefler SJ, Eigen H. Budesonide inhalation suspension: A nebulized corticosteroid for persistent asthma. J Allergy Clin Immunol 2002; 109:730-742.
37. Bisgaard H, Gillies J, Groenewald M, Maden C. The effect of inhaled fluticasone propionate in the treatment of young asthmatic children. A dose comparison study. Am J Respir Crit Care Med 1999; 160:126-131.
38. 2-agonist in asthmatic children under age 5. J Asthma 2004; 41:575-582.